Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Vitovski, Srdjan ^a   Chantry, Andrew D ^a   Lawson, Michelle A ^a   Croucher, Peter I ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEXAMETHASONE; DOXORUBICIN; LIPOCORTIN 5; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SYNDECAN 1; ANTINEOPLASTIC AGENT; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RESISTANCE; CELL ISOLATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHENOTYPE; PLASMACYTOMA; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; MICE; MULTIPLE MYELOMA; SYNDECAN-1; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861212822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035830     Document Type: Article

References (51)

1. Kyle RA, Rajkumar SV, (2004) Multiple myeloma. N Engl J Med 351: 1860-1873.
2. Hjorth M, Holmberg E, Rodjer S, Turesson I, Westin J, et al. (1999) Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG). Eur J Haematol 62: 271-277.
3. Gregory WM, Richards MA, Malpas JS, (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 334-342.
4. Myeloma trial lists collaborative group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16: 3832-3842.
5. Kyle RA, (2000) The role of high-dose chemotherapy in the treatment of multiple myeloma: A controversy. Annals of Oncology 11: S55-S58.
6. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132.
7. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 908-917.
8. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, et al. (1979) The chemotherapy on plasma-cell myeloma and the incidence of acute leukaemia. N Engl J Med 301: 743-746.
9. Cuzick J, Erskine S, Edelman D, Galton DA, (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia an adults. Br J Cancer 55: 523-529.
10. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, et al. (1996) Preceding standard therapy is the likely cause of MDS after autotransplant for multiple myeloma. Br J Haematol 95: 349-353.
11. Peya T, Morrison SJ, Clarke MF, Weissman IL, (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
12. Jones RJ, Armstrong SA, (2008) Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant 14: 12-16.
13. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
14. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
15. Xin L, Lawson DA, Witte ON, (2005) The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumourigenesis. Proc Natl Acad Sci USA 102: 6942-6947.
16. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
17. Hamburger AW, Salmon SE, (1977) Primary bioassay of human tumor stem cells. Science 197: 461-463.
18. Billadeau D, Ahmann G, Greipp P, Van Ness B, (1992) The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med 178: 1023-1031.
19. Lowe SW, Lin AW, (2000) Apoptosis in cancer. Carcinogenesis 21: 485-495.
20. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
21. Johnstone RW, Rueffi AA, Lowe SW, (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164.
22. Jagani Z, Khosravi-Far R, (2008) Cancer stem cells and impaired apoptosis. Adv Exp Med Biol 615: 331-344.
23. Fulda S, (2008) Tumor resistance to apoptosis. Int J Cancer 124: 511-515.
24. Ashkenazi A, Dixit VM, (1998) Death receptors: Signalling and modulation. Science 281: 1305-1308.
25. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP, (2001) Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs 10: 1521-1530.
26. Ashkenazi A, (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2: 420-430.
27. Bodmer J-L, Schneider P, Tschopp J, (2002) The molecular architecture of the TNF superfamily. TRENDS Biochem Sci 27: 19-26.
28. LeBlanc HN, Ashkenazi A, (2003) Apo2L and its death and decoy receptors. Cell Death and Differentiation 10: 66-75.
29. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
30. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
31. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, et al. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161-169.
32. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, et al. (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361.
33. Zerafa N, Westwood JA, Cretney E, Mitchell M, Waring P, (2005) Cutting edge: TRAIL deficiency accelerates haematological malignancies. J Immunol 175: 5586-5590.
34. Lincz LF, Yeh T-X, Spencer A, (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrow is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15: 1650-1657.
35. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, et al. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98: 795-804.
36. Jazirexi AR, Ng C-P, Gan X-H, Schiller G, Bonavida B, (2001) Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/Tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res 7: 3874-3883.
37. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK, (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400.
38. Shankar S, Chen X, Srivastava RK, (2005) Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62: 165-186.
39. Vitovski S, Phillips JS, Sayers JR, Croucher PI, (2007) Investigating the interaction between osteoprotegerin and RANKL or TRAIL: Evidence for a pivotal role for osteoprotegerin in regulating two distinc pathways. J Biol Chem 282: 31601-31609.
40. Gazitt Y, (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13: 1817-1824.
41. Shipman CM, Croucher PI, (2003) Osteoprotegerin is a soluble decoy receptor for TRAIL/Apo2L and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916.
42. Fulda S, Pervaiz S, (2010) Apoptosis signalling in cancer stem cells. Int J Biochem Cell Biol 42: 31-38.
43. Kim K, Fisher MJ, Xu S-Q, El-Deiry WS, (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346.
44. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, et al. (2005) Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65: 2344-2352.
45. Abe S, Hasegawa M, Yamamoto K, Kurata M, Nakagawa Y, et al. (2007) Rapid induction of IAP family proteins and Smac/DIABLO expression after proapoptotic stimulation with doxorubicin in RPMI 8226 multiple myeloma line. Exp Mol Pathol 83: 405-412.
46. Dumitru CA, Carpinteiro A, Trarbach T, Hengge U, Gulbins E, (2007) Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 12: 1533-1541.
47. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, et al. (2008) Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68: 3243-3250.
48. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, et al. (2010) High frequencies of leukaemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 11: 1859-1866.
49. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, et al. (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853.
50. Thai LM, Labrinidis A, Hay S, Liapis V, Bouralexis S, et al. (2006) Apo2/ tumor necrosis factor-related apoptosis-induced bone destruction in a mouse model. Cancer Res 66: 5363-5370.
51. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buhler P, et al. (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12: 2640-2646.